Benzinga·2026-01-08 08:13Group 1 - Revolution Medicines Inc. shares fell in after-hours trading following AbbVie Inc.'s denial of acquisition talks, reversing a previous 28% rally due to speculation [1][3] - AbbVie was reported to be in advanced talks to acquire Revolution Medicines, although no terms or purchase price were disclosed, and other potential suitors were also interested in Revolution [2][4] - Before the acquisition speculation, Revolution Medicines had a market capitalization of approximately $16 billion, which surged to nearly $20 billion after the news [3] Group 2 - AbbVie, with a market value exceeding $400 billion, is focusing on acquiring early-stage platforms and technologies to enhance long-term growth, including recent multibillion-dollar oncology deals [4] - Revolution Medicines' experimental cancer drugs are primarily in development, with some not yet entering human trials [4] - RVMD shares have more than doubled in the past year, reflecting a broader rebound in biotech stocks, but fell 11.5% in extended trading after a 28.6% increase to $102.71 [5] - AbbVie shares experienced a nearly 1% decline in extended trading after a 4.2% increase to $233.42, with the stock gaining over 30% in value over the past year [6]